^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NIB103

    i
    Other names: NIB103, TAK-103, NIB-103
    Associations

    News

    Trials
    Company:
    Noile-Immune Biotech
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=2, Terminated, Takeda | Trial completion date: Oct 2027 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2027 --> Feb 2025; Business decision unrelated to patient safety
    Trial completion date • Trial termination • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    NIB103
    almost2years
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=21 --> 2
    Enrollment closed • Enrollment change • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NIB103
    over2years
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Recruiting, Takeda | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NIB103
    almost4years
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NIB103
    almost4years
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Takeda
    New P1 trial
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NIB103